Landos Biopharma Inc Quick Ratio (LABP) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Landos Biopharma Inc   (NASDAQ: LABP)

Landos Biopharma Inc 's Quick Ratio

LABP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 4.3 below Landos Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 246 other companies have achieved higher Quick Ratio than Landos Biopharma Inc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 498 to 912.

Explain Quick Ratio?
How much Cash & cash equivalents LABP´s has?
What are LABP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LABP Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change 62.07 % 2.07 % 1.66 % -53.69 % -73.17 %
Y / Y Cash & cash equivalent Change -42 % -15.55 % -11.5 % -19.76 % -32.24 %
Quick Ratio MRQ 4.3 6 7.63 14.84 12.02
LABP's Total Ranking # 912 # 498 # 432 # 326 #
Seq. Current Liabilities Change 7.89 % 12.27 % 84.61 % -27.52 % -32.05 %
Seq. Cash & cash equivalent Change -22.65 % -11.7 % -5.07 % -10.54 % 12.62 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 247
Healthcare Sector # 421
Overall Market # 912


Quick Ratio Statistics
High Average Low
14.84 8.05 2.63
(Jun 30 2023)   (Dec 31 2020)




Financial Statements
Landos Biopharma Inc 's Current Liabilities $ 7 Millions Visit LABP's Balance sheet
Landos Biopharma Inc 's Cash & cash equivalent $ 29 Millions Visit LABP's Balance sheet
Source of LABP's Sales Visit LABP's Sales by Geography


Cumulative Landos Biopharma Inc 's Quick Ratio

LABP's Quick Ratio for the trailling 12 Months

LABP Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth -3.12 % -43.51 % -57.23 % -62.25 % -60.05 %
Y / Y Cash & cash equivalent TTM Growth -22.43 % -21.28 % -32.34 % -42.08 % -48.19 %
Quick Ratio TTM 7.13 9.2 9.63 9.97 8.9
Total Ranking TTM # 3419 # 3322 # 3474 # 5240 #
Seq. Current Liabilities TTM Growth 13.6 % 0.67 % 0.48 % -15.7 % -33.76 %
Seq. Cash & cash equivalent TTM Growth -12.02 % -3.8 % -2.95 % -5.56 % -10.72 %

Quick ratio ranking by company, industry and sector >> Back to LABP Financial Strength Comparisons >> Go to Compare LABP Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2024 to $6.74 millions, cumulative Quick Ratio decreased to 7.13 below the Landos Biopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 465 other companies have achieved higher Quick Ratio than Landos Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 3322 to 3419.

Explain Quick Ratio?
How much Cash & cash equivalents LABP´s has?
What are LABP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 466
Healthcare Sector # 922
Within the Market # 3419


trailing twelve months Quick Ratio Statistics
High Average Low
9.04 7.2 5.02
(Dec 31 2023)   (Jun 30 2021)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Ovid Therapeutics Inc   11.82 $ 90.259  Millions$ 7.635  Millions
Sensei Biotherapeutics Inc   11.63 $ 58.081  Millions$ 4.992  Millions
Anaptysbio Inc   11.63 $ 354.665  Millions$ 30.485  Millions
Cormedix Inc   11.57 $ 110.266  Millions$ 9.534  Millions
Adc Therapeutics Sa  11.52 $ 234.285  Millions$ 20.344  Millions
Rezolute Inc   11.50 $ 80.022  Millions$ 6.957  Millions
Boundless Bio Inc   11.50 $ 104.880  Millions$ 9.121  Millions
Spyre Therapeutics Inc   11.32 $ 484.641  Millions$ 42.818  Millions
Actinium Pharmaceuticals Inc  11.19 $ 84.057  Millions$ 7.513  Millions
Kezar Life Sciences Inc   11.13 $ 179.798  Millions$ 16.161  Millions
Pyxis Oncology Inc   11.10 $ 157.027  Millions$ 14.141  Millions
An2 Therapeutics Inc   11.04 $ 114.210  Millions$ 10.342  Millions
Praxis Precision Medicines Inc   11.04 $ 207.416  Millions$ 18.794  Millions
Xenetic Biosciences Inc   10.92 $ 7.824  Millions$ 0.717  Millions
Eupraxia Pharmaceuticals Inc   10.92 $ 33.101  Millions$ 3.032  Millions
Bright Minds Biosciences Inc   10.91 $ 4.420  Millions$ 0.405  Millions
Mural Oncology Plc  10.90 $ 231.674  Millions$ 21.247  Millions
Merrimack Pharmaceuticals Inc  10.77 $ 244.110  Millions$ 22.672  Millions
Day One Biopharmaceuticals Inc   10.76 $ 317.944  Millions$ 29.539  Millions
Io Biotech Inc   10.68 $ 117.982  Millions$ 11.043  Millions
Cocrystal Pharma Inc   10.21 $ 21.842  Millions$ 2.139  Millions
Eledon Pharmaceuticals Inc   10.09 $ 42.862  Millions$ 4.247  Millions
Immunome Inc   10.07 $ 309.706  Millions$ 30.768  Millions
Cerevel Therapeutics Holdings Inc   10.06 $ 846.294  Millions$ 84.104  Millions
Rocket Pharmaceuticals Inc   10.02 $ 330.313  Millions$ 32.957  Millions
Lantern Pharma Inc   9.70 $ 38.358  Millions$ 3.953  Millions
Rafael Holdings Inc  9.60 $ 72.377  Millions$ 7.541  Millions
Maravai Lifesciences Holdings Inc   9.52 $ 561.691  Millions$ 59.022  Millions
Olema Pharmaceuticals Inc   9.49 $ 248.977  Millions$ 26.224  Millions
Alpine Immune Sciences Inc   9.48 $ 305.661  Millions$ 32.238  Millions

Date modified: 2026-09-08T15:22:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.